[A modified pathological N1 classification strategy based on the systematic dissection of N1 nodes for non-small cell lung cancer]

Zhonghua Yi Xue Za Zhi. 2021 Sep 21;101(35):2748-2750. doi: 10.3760/cma.j.cn112137-20210621-01402.
[Article in Chinese]

Abstract

The Tumor, Node, Metastasis (TNM) staging system has been adopted by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) for approximately 50 years. The N1 descriptor has rarely been modified since it was first proposed. Nevertheless, heterogeneity of the N1 disease should be prioritized because the survival outcomes vary greatly in N1 cohort. It has been discovered that prognostic differences exist between various patterns of N1 lymph node metastasis in previous studies. However, the absence of stations 13/14 lymph nodes data has always been an urgent problem to be solved. On the premise of complete intrapulmonary lymph node retrieval, based on the clinical experience our team had accumulated, we used subcategories within the N1 descriptor based on the location of involved N1 lymph nodes. We defined new N1a as involvement of peripheral zone lymph nodes (stations 12-14), and new N1b as involvement of hilar zone lymph nodes (stations 10-11). This new system could improve the ability to identify the heterogeneity of N1 disease. We propose that this modified classification strategy can be used as a more effective N1 descriptor.

肿瘤、淋巴结与转移(TNM)分期系统已被国际抗癌联盟(UICC)及美国癌症联合会(AJCC)采纳接近50年,在此期间N1淋巴结评估标准几乎没有被修订过。但是,N1病变的异质性必须被重视,因为不同N1期患者之间生存情况差异巨大。既往研究中探索了不同N1淋巴结转移情况对预后影响的差异,但缺乏13/14组淋巴结信息一直是亟须解决的问题。在肺内淋巴结分检的前提下,本研究团队在积累临床经验的基础上,根据N1转移淋巴结的解剖位置进行N分期:累及肺内区淋巴结(12~14组)被定义为新N1a,累及肺门区淋巴结(10~11组)被定义为新N1b。改良的分期方法能够更好地辨识N1病变异质性,因而被认为是一种更为有效的N1淋巴结分期策略。.

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Dissection
  • Humans
  • Lung Neoplasms* / pathology
  • Lymph Nodes
  • Lymphatic Metastasis
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies